Free Trial

Mersana Therapeutics (MRSN) Insider Trading & Ownership

Mersana Therapeutics logo
$1.60 -0.14 (-8.05%)
(As of 12/20/2024 05:51 PM ET)

Mersana Therapeutics (NASDAQ:MRSN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
11.80%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
7
Amount Of
Insider Selling
(Last 12 Months)
$256,846.84
Get MRSN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Mersana Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

MRSN Insider Buying and Selling by Quarter

Mersana Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2024Mohan BalaSVPSell1,884$1.90$3,579.60  
10/3/2024Alejandra CarvajalSVPSell5,598$1.96$10,972.08  
10/2/2024Ashish MandeliaCAOSell4,855$2.00$9,710.00  
10/2/2024Brian DeschuytnerCFOSell8,089$2.00$16,178.00  
9/12/2024Martin H Jr. HuberCEOSell50,423$1.76$88,744.48  
1/16/2024Anna ProtopapasDirectorSell29,399$2.71$79,671.29  
1/16/2024Ashish MandeliaCAOSell5,025$2.71$13,617.75  
1/16/2024Brian DeschuytnerCFOSell9,327$2.71$25,276.17  
1/16/2024Tushar MisraSVPSell3,357$2.71$9,097.47  
(Data available from 1/1/2013 forward)

MRSN Insider Trading Activity - Frequently Asked Questions

The list of insiders at Mersana Therapeutics includes Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Martin H Jr. Huber, Mohan Bala, Timothy B Lowinger, and Tushar Misra. Learn more on insiders at MRSN.

11.80% of Mersana Therapeutics stock is owned by insiders. Learn more on MRSN's insider holdings.

The following insiders have sold MRSN shares in the last 24 months: Alejandra Carvajal ($26,314.24), Anna Protopapas ($179,237.33), Arvin Yang ($12,679.66), Ashish Mandelia ($43,848.25), Brian Deschuytner ($70,906.11), Martin H Jr. Huber ($88,744.48), Mohan Bala ($5,740.16), and Tushar Misra ($13,977.83).

Insiders have sold a total of 154,440 Mersana Therapeutics shares in the last 24 months for a total of $441,448.06 sold.

Mersana Therapeutics Key Executives

  • Dr. Martin H. Huber M.D. (Age 63)
    President, CEO & Director
    Compensation: $44k
  • Mr. Brian C. DeSchuytner (Age 45)
    Senior VP, CFO & COO
    Compensation: $626.32k
    1 recent trades
  • Dr. Timothy B. Lowinger Ph.D. (Age 60)
    Senior VP and Chief Science & Technology Officer
    Compensation: $666.3k
  • Ms. Alejandra Veronica Carvajal J.D. (Age 50)
    Senior VP, Secretary & Chief Legal Officer
    Compensation: $606.51k
  • Mr. Mikhail Papisov Ph.D.
    Co-Founder
  • Mr. Ashish  MandeliaMr. Ashish Mandelia (Age 49)
    VP, Controller & Chief Accounting Officer
    1 recent trades
  • Mr. Jason Fredette
    Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Chuck Miller
    Senior Vice President of Regulatory Affairs
  • Mr. Marc Damelin
    Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.
  • Dr. Tushar Misra Ph.D. (Age 63)
    Senior VP & Chief Manufacturing Officer
    Compensation: $485.89k


This page (NASDAQ:MRSN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners